SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Status:
Completed
Trial end date:
2013-02-09
Target enrollment:
Participant gender:
Summary
This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre
study for subjects with trauma (physical injury) who are at risk for developing Acute Lung
Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The primary purpose of the study
is to evaluate the safety and tolerability of SB-681323, which is a potent, selective
inhibitor of p38 alpha (MAPK) (prevents inflammation of tissue), in comparison to a placebo.